There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
Human Genome Sciences
Central European Distribution
MF Global shed more than two-thirds of its value on concerns that the futures broker doesn't have the financial fortitude to survive after betting on the wrong side of the European sovereign debt crisis. MF Global spent the weekend desperately seeking a suitor for a quick shotgun wedding.
Netflix stunned investors by projecting losses early next year as it begins to expand into Europe. It also didn't help that its domestic subscribers clocked in lower than the company's mid-September guidance.
TriQuint took a hit after following up mixed quarterly results with uninspiring guidance for the current quarter. The radio frequency specialist beat Wall Street's bottom-line target but came up short on the top line.
Human Genome Sciences took a hit after reporting weaker-than-expected revenue in its latest quarter. Investors had high hopes for Benlysta, the first new lupus drug to hit the market in ages. It may still prove to be a long-term winner, but sales have been slow in ramping up.
Central European Distribution took a hit as more than a dozen class action lawsuits were initiated against the vodka maker, alleging that Central European Distribution failed to disclose unflattering news on a timely basis.
It was a rough week for these five stocks. Let's see if they bounce back.
Motley Fool newsletter services have recommended buying shares of Netflix and Central European Distribution. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story, except for Netflix. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
More from The Motley Fool
3 Disruptive Stocks That Justify Their High Valuations
For long-term holders, it pays to pay up for disruptive potential.
Netflix Earnings: What to Watch
Can Netflix convince investors it can maintain strong momentum in 2018?
Could Netflix Produce Disney-Sized Revenue Someday?
At least one analyst thinks so and predicts Netflix will rank second in the next three to five years.